Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: A Randomized Controlled Study

Ophthalmology

Volumn 123, Issue 5, 2016, Pages 1080-1089

  Holz, Frank G ^a   Dugel, Pravin U ^b,c   Weissgerber, Georges ^d   Hamilton, Robin ^e   Silva, Rufino ^f   Bandello, Francesco ^g   Larsen, Michael ^h   Weichselberger, Andreas ^d   Wenzel, Andreas ^d   Schmidt, Anne ⁱ   Escher, Dominik ⁱ   Sararols, Laura ^j   Souied, Eric ^k  

^a UNIVERSITY OF BONN   (Germany)

^b RETINAL CONSULTANTS OF ARIZONA   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d A Novartis Company   (United States)

^e MOORFIELDS EYE HOSPITAL   (United Kingdom)

^f CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^g VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^h UNIVERSITY OF COPENHAGEN   (Denmark)

ⁱ A Novartis Company   (Switzerland)

^j HOSPITAL GENERAL DE CATALUNYA   (Spain)

^k CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; RTH 258; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; IMMUNOGLOBULIN FRAGMENT; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; AGED; AREA UNDER THE CURVE; BACKACHE; BEST CORRECTED VISUAL ACUITY; BRONCHITIS; CENTRAL SUBFIELD THICKNESS; CHOROIDITIS; CONFERENCE PAPER; CONJUNCTIVAL HEMORRHAGE; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; CORNEA DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRY EYE; EYE IRRITATION; EYE PAIN; FEMALE; FOREIGN BODY; HUMAN; HYPERTENSION; IRIDOCYCLITIS; IRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA HEMORRHAGE; RETINA MACULOPATHY; RHINOPHARYNGITIS; SINGLE DRUG DOSE; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; URINARY TRACT INFECTION; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS; VITREOUS FLOATERS; VITRITIS; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPARATIVE STUDY; FLUORESCENCE ANGIOGRAPHY; IMMUNOLOGY; INTRAVITREAL DRUG ADMINISTRATION; OPTICAL COHERENCE TOMOGRAPHY; PATHOPHYSIOLOGY; TREATMENT OUTCOME; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DOUBLE-BLIND METHOD; FEMALE; FLUORESCEIN ANGIOGRAPHY; HUMANS; IMMUNOGLOBULIN FRAGMENTS; INTRAVITREAL INJECTIONS; MALE; PROSPECTIVE STUDIES; RANIBIZUMAB; SINGLE-CHAIN ANTIBODIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84958580966     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2015.12.030     Document Type: Conference Paper

References (22)

1. J.B. Jonas, R.R. Bourne, R.A. White, and et al. Visual impairment and blindness due to macular diseases globally: a systematic review and meta-analysis Am J Ophthalmol 158 2014 808 815
2. F.G. Holz, S. Schmitz-Valckenberg, and M. Fleckenstein Recent developments in the treatment of age-related macular degeneration J Clin Invest 124 2014 1430 1438
3. S.B. Bloch, M. Larsen, and I.C. Munch Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010 Am J Ophthalmol 153 2012 209 213 e2
4. A. Skaat, A. Chetrit, M. Belkin, and et al. Time trends in the incidence and causes of blindness in Israel Am J Ophthalmol 153 2012 214 221 e1
5. ® Guidelines. Age-related macular degeneration. Available at: http://www.aao.org/preferred-practice-pattern/age-related-macular-degeneration-ppp-2015 Accessed July 31, 2015.
6. U. Schmidt-Erfurth, V. Chong, A. Loewenstein, and et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA) Br J Ophthalmol 98 2014 1144 1167
7. M. Ishikawa, D. Jin, Y. Sawada, and et al. Future therapies of wet age-related macular degeneration J Ophthalmol 2015 2015 138070
8. E.H. Souied, B. Gekkiev, A. Bretagne, and et al. Ranibizumab in a real-world clinical setting: 2014 interim analysis of the 5-year observational multicenter LUMINOUS study Invest Ophthalmol Vis Sci 56 2015 1417
9. D.M. Brown, P.K. Kaiser, M. Michels, and et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444
10. P.J. Rosenfeld, D.M. Brown, J.S. Heier, and et al. Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431
11. B.G. Busbee, A.C. Ho, D.M. Brown, and et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration Ophthalmology 120 2013 1046 1056
12. D.F. Martin, M.G. Maguire, G.S. Ying, and et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 2011 1897 1908
13. F.G. Holz, R. Tadayoni, S. Beatty, and et al. Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration Br J Ophthalmol 99 2015 220 226
14. P.K. Kaiser Emerging therapies for neovascular age-related macular degeneration: drugs in the pipeline Ophthalmology 120 2013 S11 S15
15. J. Tietz, G. Schmid, J. Konrad, and et al. Affinity and potency of RTH258 (ESBA1008), a novel inhibitor of vascular endothelial growth factor a for the treatment of retinal disorders Invest Ophthalmol Vis Sci 56 2015 1501
16. J. Gaudreault, T. Gunde, H.S. Floyd, and et al. Preclinical pharmacology and safety of ESBA1008, a single-chain antibody fragment, investigated as potential treatment for age related macular degeneration [abstract] Invest Ophthalmol Vis Sci 53 2012 3025
17. Singerman LJ, Weichselberger A, Sallstig P. OSPREY trial: randomized, active-controlled, phase II study to evaluate safety and efficacy of RTH258, a humanized single-chain anti-VEGF antibody fragment, in patients with neovascular AMD. Presented at: ARVO; May 6, 2015, Denver, Colorado.
18. J.S. Heier, D.M. Brown, V. Chong, and et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration Ophthalmology 119 2012 2537 2548
19. G.S. Ying, B.J. Kim, M.G. Maguire, and et al. Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials JAMA Ophthalmol 132 2014 915 921
20. A.C. Ho, B.G. Busbee, C.D. Regillo, and et al. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration Ophthalmology 121 2014 2181 2192
21. C.V. Regatieri, L. Branchini, and J.S. Duker The role of spectral-domain OCT in the diagnosis and management of neovascular age-related macular degeneration Ophthalmic Surg Lasers Imaging 42 Suppl 2011 S56 S66
22. U. Schmidt-Erfurth, B. Eldem, R. Guymer, and et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study Ophthalmology 118 2011 831 839